Literature DB >> 19936983

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Filippo Bellati1, Chiara Napoletano, Ilary Ruscito, Maria Pastore, Milena Pernice, Morena Antonilli, Marianna Nuti, Pierluigi Benedetti Panici.   

Abstract

Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life. Here we report the case of a patient who benefited from complete resolution of ascites after low dose intraperitoneal administration of bevacizumab. Immunological analyses showed an initial increase in proportion and function of CD8(+) effector T cells and a reduction of circulating T(reg) cells. A review of the current literature regarding bevacizumab in ovarian cancer is reported. Bevacizumab has shown a high efficacy in the treatment of ovarian cancer. Intraperitoneal administration induces an immune activation and appears promising in the treatment of malignant ascites.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19936983     DOI： 10.1007/s10637-009-9351-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  48 in total

1.  Survival of patients following secondary cytoreductive surgery in ovarian cancer.

Authors:  J S Berek; N F Hacker; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-02       Impact factor: 7.661

2.  Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.

Authors:  S Sartori; I Nielsen; D Tassinari; L Trevisani; V Abbasciano; P Malacarne
Journal:  Oncology       Date:  2001       Impact factor: 2.935

3.  Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.

Authors:  A Bamias; M L Tsiatas; E Kafantari; C Liakou; A Rodolakis; Z Voulgaris; G Vlahos; T Papageorgiou; O Tsitsilonis; C Bamia; G Papatheodoridis; Ek Politi; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-04-11       Impact factor: 5.482

Review 4.  Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited.

Authors:  J T Tamsma; H J Keizer; A E Meinders
Journal:  Ann Oncol       Date:  2001-10       Impact factor: 32.976

5.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Authors:  Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

6.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

8.  The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Authors:  Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse
Journal:  Cancer Immunol Immunother       Date:  2008-01-10       Impact factor: 6.968

9.  Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.

Authors:  N Arora; D Tewari; C Cowan; B Saffari; B J Monk; R A Burger
Journal:  Int J Gynecol Cancer       Date:  2007-07-11       Impact factor: 3.437

10.  The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.

Authors:  Junji Wada; Hiroyuki Suzuki; Ryouta Fuchino; Akio Yamasaki; Shuntaro Nagai; Kousuke Yanai; Kenichiro Koga; Masafumi Nakamura; Masao Tanaka; Takashi Morisaki; Mitsuo Katano
Journal:  Anticancer Res       Date:  2009-03       Impact factor: 2.480
View more
  14 in total

1.  Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.

Authors:  Claudia Marchetti; Filippo Bellati; Angela Musella; Chiara Napoletano; Giorgia Perniola; Violante Di Donato; Sandro Pignata; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Int J Clin Oncol       Date:  2011-09-03       Impact factor: 3.402

2.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

Review 3.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

4.  Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.

Authors:  Aflah Roohullah; Hui-Li Wong; Katrin M Sjoquist; Peter Gibbs; Kathryn Field; Ben Tran; Jeremy Shapiro; Joe Mckendrick; Desmond Yip; Louise Nott; Val Gebski; Weng Ng; Wei Chua; Timothy Price; Niall Tebbutt; Lorraine Chantrill
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

5.  Immune effects of trastuzumab.

Authors:  Marianna Nuti; Filippo Bellati; Valeria Visconti; Chiara Napoletano; Lavinia Domenici; Jlenia Caccetta; Ilaria Grazia Zizzari; Ilary Ruscito; Hassan Rahimi; Pierluigi Benedetti-Panici; Aurelia Rughetti
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207

6.  Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.

Authors:  Francesco Legge; Amelia Paglia; Marco D'Asta; Gilda Fuoco; Giovanni Scambia; Gabriella Ferrandina
Journal:  BMC Cancer       Date:  2011-05-31       Impact factor: 4.430

Review 7.  Monoclonal antibodies in gynecological cancer: a critical point of view.

Authors:  Filippo Bellati; Chiara Napoletano; Maria Luisa Gasparri; Valeria Visconti; Ilaria Grazia Zizzari; Ilary Ruscito; Jlenia Caccetta; Aurelia Rughetti; Pierluigi Benedetti-Panici; Marianna Nuti
Journal:  Clin Dev Immunol       Date:  2011-12-26

8.  BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.

Authors:  Wouter Willaert; Kurt Van Der Speeten; Gabriel Liberale; Wim Ceelen
Journal:  BMC Cancer       Date:  2015-12-16       Impact factor: 4.430

Review 9.  Update on vaccine development for renal cell cancer.

Authors:  Nina Chi; Jodi K Maranchie; Leonard J Appleman; Walter J Storkus
Journal:  Open Access J Urol       Date:  2010-08-04

10.  Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer.

Authors:  Jun Yu; Yan Ma; Jeanne Drisko; Qi Chen
Journal:  Curr Ther Res Clin Exp       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.